Gubra

506,00 DKK

−1,65 %

Under 1K följer bolaget

GUBRA

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Översikt

Nyckeltal & Estimat

Ägarlista

Investerarkonsensus

Jämför

−1,65 %

−2,22 %

−0,10 %

+17,40 %

+21,99 %

−24,02 %

+360,00 %

Gubra är ett läkemedelsbolag. Bolagets verksamhet är fokuserad på de tidiga stadierna av läkemedelsutveckling. De driver huvudsakligen forskning och utveckling inom området för metabola och fibrotiska sjukdomar. Bolagets produktportfölj innefattar ett flertal varumärken och läkemedel, och verksamheten bedrivs på global nivå, med störst närvaro inom Nordamerika och Norden. Huvudkontoret ligger i Hørsholm, Danmark.

Läs mera

Börsvärde

8,27 md DKK

Omsatt (värde)

1,2 mn DKK

Omsättning

EBIT%

P/E

Direktavkastnings- %

Bevakning

Disclaimer

Michael Friis, Philip Coombes

Visa mera

Senaste analysen

Latest analysis report

Released: 17.03.2025

Omsättning & EBIT-%

Omsättning mn

EBIT-%

Vinst per aktie & Utdelning

EPS (adj.)

Direktavkastning

Finansiell kalender

27.2.

2026

Bokslutskommuniké '25

Alla

Analys

Webcasts

Pressmeddelanden

VisarAlla typer av innehåll

Pressmeddelande2026-01-08 12:00

Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra

Gubra

Pressmeddelande2026-01-05 06:30

Gubra appoints Dr. Thomas Langenickel as Chief Medical and Development Officer

Gubra

Pressmeddelande2026-01-02 06:30

Gubra Announces Expansion of Facilities to Support Continued Growth Across Its Businesses

Gubra

Välkommen med i Inderes community!

Skapa ett gratis användarkonto och försäkra dig om att inte missa några börsnyheter av intresse för precis dig!

FREE account

Stock market's most popular morning newsletter

Tillgång till analytikerkommentarer och rekommendationer

Vårt eget aktiescreeningsverktyg

PREMIUM account

Alla aktieanalyser och övrigt innehåll

Premiumverktyg (insidertransaktioner och aktiescreeningsverktyg)

Inderes modellportfölj

Skapa användarkonto

Regulatoriskt pressmeddelande2025-12-17 12:49

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Gubra

Analytikerkommentar2025-12-16 12:53 av

Philip Coombes

Gubra – Nytt partnerskap med Camurus för att utveckla en långtidsverkande behandling för hypoparatyreoidism

Gubra har ingått ett exklusivt samarbets- och licensavtal med Camurus för att utveckla en långtidsverkande behandling för hypoparatyreoidism. Behandlingen kombinerar Gubras parathormon (PTH)-analog (upptäckt via dess AI-drivna streaMLine-plattform) med Camurus FluidCrystal®-teknologi för fördröjd frisättning. Målet är att minska injektionsfrekvensen och förbättra sjukdomskontrollen jämfört med nuvarande PTH-behandlingar som ges en gång dagligen, vilket åtgärdar ett tydligt ouppfyllt behov vid denna sällsynta endokrina sjukdom.

Gubra

Pressmeddelande2025-12-16 10:30

Gubra and Camurus Enter into a Collaboration and License Agreement to Develop a Long-acting Treatment for Hypoparathyroidism

Gubra

Regulatoriskt pressmeddelande2025-12-08 07:00

Boehringer Ingelheim advances next generation triple-agonist peptide for the treatment of obesity into mid-stage development

Gubra

Regulatoriskt pressmeddelande2025-11-10 20:23

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Gubra

Regulatoriskt pressmeddelande2025-11-10 16:29

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Gubra

Regulatoriskt pressmeddelande2025-11-07 17:03

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Gubra

Regulatoriskt pressmeddelande2025-11-07 06:30

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Gubra

Regulatoriskt pressmeddelande2025-07-10 20:07

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Gubra

Regulatoriskt pressmeddelande2025-06-30 07:51

Gubra shares are traded ex-dividend

Gubra

Regulatoriskt pressmeddelande2025-06-27 11:09

COURSE OF GUBRA A/S' EXTRAORDINARY GENERAL MEETING REGARDING EXTRAORDINARY DIVIDEND

Gubra

Gubra

506,00 DKK

−1,65 %

Bevakning

Senaste analysen

Omsättning & EBIT-%

Vinst per aktie & Utdelning

Finansiell kalender

Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra

Gubra appoints Dr. Thomas Langenickel as Chief Medical and Development Officer

Gubra Announces Expansion of Facilities to Support Continued Growth Across Its Businesses

Välkommen med i Inderes community!

FREE account

PREMIUM account

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Gubra – Nytt partnerskap med Camurus för att utveckla en långtidsverkande behandling för hypoparatyreoidism

Gubra and Camurus Enter into a Collaboration and License Agreement to Develop a Long-acting Treatment for Hypoparathyroidism

Boehringer Ingelheim advances next generation triple-agonist peptide for the treatment of obesity into mid-stage development

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Trading statement Q3-2025: Expanding our R&D activities

Record earnings for Gubra; revised outlook for the CRO business

Gubra Announces Completion of Solar & Battery Park

Interim report H1 2025: Group revenue and earnings record-high

Record quarter for Gubra, but revised outlook for the CRO business

Markus Rohrwild appointed new CEO of Gubra in a planned succession process

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Gubra shares are traded ex-dividend

COURSE OF GUBRA A/S' EXTRAORDINARY GENERAL MEETING REGARDING EXTRAORDINARY DIVIDEND